The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI.

Mochtar MH

Human reproduction (Oxford, England)30 Jun 2004Cited by 44 (Europe PMC)

PMID15229205DOI10.1093/humrep/deh334PepBankPUB-15229205

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI patients, retrieved oocytes did not differ significantly between flexible ganirelix (9.4, SD 5.8) and fixed ganirelix (9.7, SD 6.5).
In plain wordsIn IVF/ICSI patients, retrieved oocytes did not differ significantly between flexible ganirelix and fixed ganirelix.
Peptide
Ganirelix
Outcome
No significant changeRetrieved oocytes
Study
n = 205
Comparator
fixed ganirelix regimen starting on stimulation day 6
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg dailyAs given in this study (human).
Measurements
Mean retrieved oocytes
9.4 oocytes
flexible regimen
SD of retrieved oocytes
5.8 oocytes
flexible regimen
Mean retrieved oocytes
9.7 oocytes
fixed regimen
SD of retrieved oocytes
6.5 oocytes
fixed regimen
Source sentences
Summary
The mean (SD) number of retrieved oocytes was not statistically significantly different: 9.4 (5.8) in the flexible group versus 9.7 (6.5) in the fixed group.
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre, randomized, clinical trial, IVF/ICSI patients were allocated to a standard regimen, in which they received daily 0.25 mg GnRH antagonist ganirelix (Orgalutran) from the 6th day of stimulation onward (fixed regimen n = 102)
Summary · context
or to an individualized regimen, in which IVF/ICSI patients received daily 0.25 mg GnRH antagonist starting on the day that the dominant follicle had reached a diameter of > or = 15 mm (flexible regimen n = 103).
Report a problemFND-1522920501
02HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI patients, clinical pregnancy rates were 22.7% with flexible ganirelix versus 33% with fixed ganirelix, relative rate ratio 0.69 (95% CI 0.44-1.08).
In plain wordsIn IVF/ICSI patients, clinical pregnancy rates were 22.7% with flexible ganirelix versus 33% with fixed ganirelix.
Peptide
Ganirelix
Outcome
DecreaseClinical pregnancy rate
Study
n = 205
Comparator
fixed ganirelix regimen starting on stimulation day 6
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg dailyAs given in this study (human).
Measurements
Clinical pregnancy rate
22.7%
flexible regimen
Clinical pregnancy rate
33%
fixed regimen
Relative rate ratio
0.69 ratio
flexible versus fixed
95% confidence interval of relative rate ratio
0.44 to 1.08 ratio
flexible versus fixed
Source sentences
Summary
The clinical and ongoing pregnancy rates were 22.7 and 21.8% respectively in the flexible group versus 33 and 31.1% in the fixed group [relative rate ratio 0.69 (95% confidence interval 0.44-1.08) and 0.7 (0.44-1.12) respectively].
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre, randomized, clinical trial, IVF/ICSI patients were allocated to a standard regimen, in which they received daily 0.25 mg GnRH antagonist ganirelix (Orgalutran) from the 6th day of stimulation onward (fixed regimen n = 102)
Summary · context
or to an individualized regimen, in which IVF/ICSI patients received daily 0.25 mg GnRH antagonist starting on the day that the dominant follicle had reached a diameter of > or = 15 mm (flexible regimen n = 103).
Report a problemFND-1522920502
03HumanRandomized controlled trialEfficacy outcome
In IVF/ICSI patients, ongoing pregnancy rates were 21.8% with flexible ganirelix versus 31.1% with fixed ganirelix, relative rate ratio 0.7 (0.44-1.12).
In plain wordsIn IVF/ICSI patients, ongoing pregnancy rates were 21.8% with flexible ganirelix versus 31.1% with fixed ganirelix.
Peptide
Ganirelix
Outcome
DecreaseOngoing pregnancy rate
Study
n = 205
Comparator
fixed ganirelix regimen starting on stimulation day 6
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg dailyAs given in this study (human).
Measurements
Ongoing pregnancy rate
21.8%
flexible regimen
Ongoing pregnancy rate
31.1%
fixed regimen
Relative rate ratio
0.7 ratio
flexible versus fixed
95% confidence interval of relative rate ratio
0.44 to 1.12 ratio
flexible versus fixed
Source sentences
Summary
The clinical and ongoing pregnancy rates were 22.7 and 21.8% respectively in the flexible group versus 33 and 31.1% in the fixed group [relative rate ratio 0.69 (95% confidence interval 0.44-1.08) and 0.7 (0.44-1.12) respectively].
2 context sentences(design, population, supporting numbers)
Summary · context
In a multicentre, randomized, clinical trial, IVF/ICSI patients were allocated to a standard regimen, in which they received daily 0.25 mg GnRH antagonist ganirelix (Orgalutran) from the 6th day of stimulation onward (fixed regimen n = 102)
Summary · context
or to an individualized regimen, in which IVF/ICSI patients received daily 0.25 mg GnRH antagonist starting on the day that the dominant follicle had reached a diameter of > or = 15 mm (flexible regimen n = 103).
Report a problemFND-1522920503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.